MELPREDICT: a logistic regression model to estimate CDKN2A carrier probability

被引:21
作者
Niendorf, K. B.
Goggins, W.
Yang, G.
Tsai, K. Y.
Shennan, M.
Bell, D. W.
Sober, A. J.
Hogg, D.
Tsao, H.
机构
[1] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Ctr Canc Risk Anal, Ctr Canc, Boston, MA 02114 USA
[3] Chinese Univ Hong Kong, Ctr Biostat & Epidemiol, Sch Publ Hlth, Hong Kong, Hong Kong, Peoples R China
[4] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA
[5] Univ Toronto, Dept Med, Toronto, ON, Canada
[6] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada
关键词
D O I
10.1136/jmg.2005.032441
中图分类号
Q3 [遗传学];
学科分类号
071007 [遗传学]; 090102 [作物遗传育种];
摘要
Background: Heritable alterations in CDKN2A account for a subset of familial melanoma cases although no robust method exists to identify those at risk of being a mutation carrier. Methods: We set out to construct a model for estimating CDKN2A mutation carrier probability using a cohort of 116 consecutive familial cutaneous melanoma patients evaluated at Massachusetts General Hospital Pigmented Lesion Center between April 2001 and September 2004. Germline CDKN2A and CDK4 status on the familial melanoma cases and clinical features associated with mutational status were then used to build a multiple logistic regression model to predict carrier probability and performance of model on external validation. Results: From the 116 kindreds prone to melanoma in the Boston area, 13 CDKN2A mutation carriers were identified and 12 were subsequently used in the modeling. Proband age at diagnosis, number of proband primaries, and number of additional family primaries were most closely associated with germline mutations. The estimated probability of the proband being a mutation carrier based on the logistic regression model (MELPREDICT) is given by e(L)/1+e(L) where L = 1.99+[0.926(no. of proband primaries)]+[0.74x(no.of additional family primaries)]-[2.11xIn((age))]. The mean estimated probabilities for subjects in the Boston dataset were 55.4% and 5.1% for the mutation carriers and non-carriers respectively. In a receiver operator characteristic analysis, the area under the curve was 0.881 (95% confidence interval 0.739 to 1.000) for the Boston model set (n = 116) and 0.803 (0.729 to 0.877) for an external Toronto hereditary melanoma cohort (n = 143). Conclusions: These results represent the first-iteration logistic regression model to approximate CDKN2A carrier probability. Validation of this model with an external dataset revealed relatively robust performance.
引用
收藏
页码:501 / 506
页数:6
相关论文
共 25 条
[1]
CDKN2A variants in a population-based sample of queensland families with melanoma [J].
Aitken, J ;
Welch, J ;
Duffy, D ;
Milligan, A ;
Green, A ;
Martin, N ;
Hayward, N .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (05) :446-452
[2]
*AM SOC CLIN ONC, 1996, J CLIN ONCOL, V14, P1737
[3]
CDKN2A germline mutations in familial pancreatic cancer [J].
Bartsch, DK ;
Sina-Frey, M ;
Lang, S ;
Wild, A ;
Gerdes, B ;
Barth, P ;
Kress, R ;
Grützmann, R ;
Colombo-Benkmann, M ;
Ziegler, A ;
Hahn, SA ;
Rothmund, M ;
Rieder, H .
ANNALS OF SURGERY, 2002, 236 (06) :730-737
[4]
Bishop DT, 2002, J NATL CANCER I, V94, P894, DOI 10.1093/jnci/94.12.894
[5]
RATES OF P16(MTS1) MUTATIONS IN PRIMARY TUMORS WITH 9P LOSS [J].
CAIRNS, P ;
MAO, L ;
MERLO, A ;
LEE, DJ ;
SCHWAB, D ;
EBY, Y ;
TOKINO, K ;
VANDERRIET, P ;
BLAUGRUND, JE ;
SIDRANSKY, D .
SCIENCE, 1994, 265 (5170) :415-416
[6]
Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO [J].
Euhus, DM ;
Smith, KC ;
Robinson, L ;
Stucky, A ;
Olopade, OI ;
Cummings, S ;
Garber, JE ;
Chittenden, A ;
Mills, GB ;
Rieger, P ;
Esserman, L ;
Crawford, B ;
Hughes, KS ;
Roche, CA ;
Ganz, PA ;
Seldon, J ;
Fabian, CJ ;
Klemp, J ;
Tomlinson, G .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2002, 94 (11) :844-851
[7]
Localization of a novel melanoma susceptibility locus to 1p22 [J].
Gillanders, E ;
Juo, SHH ;
Holland, EA ;
Jones, M ;
Nancarrow, D ;
Freas-Lutz, D ;
Sood, R ;
Park, N ;
Faruque, M ;
Markey, C ;
Kefford, RF ;
Palmer, J ;
Bergman, W ;
Bishop, DT ;
Tucker, MA ;
Bressac-de Paillerets, B ;
Hansson, J ;
Stark, M ;
Gruis, N ;
Bishop, JN ;
Goldstein, AM ;
Bailey-Wilson, JE ;
Mann, GJ ;
Hayward, N ;
Trent, J .
AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 73 (02) :301-313
[8]
Familial Melanoma, Pancreatic Cancer and Germline CDKN2A Mutations [J].
Goldstein, Alisa M. .
HUMAN MUTATION, 2004, 23 (06) :630-+
[9]
Prospective risk of cancer in CDKN2A germline mutation carriers [J].
Goldstein, AM ;
Struewing, JP ;
Fraser, MC ;
Smith, MW ;
Tucker, MA .
JOURNAL OF MEDICAL GENETICS, 2004, 41 (06) :421-424
[10]
INCREASED RISK OF PANCREATIC-CANCER IN MELANOMA-PRONE KINDREDS WITH P16(INK4) MUTATIONS [J].
GOLDSTEIN, AM ;
FRASER, MC ;
STRUEWING, JP ;
HUSSUSSIAN, CJ ;
RANADE, K ;
ZAMETKIN, DP ;
FONTAINE, LS ;
ORGANIC, SM ;
DRACOPOLI, NC ;
CLARK, WH ;
TUCKER, MA .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (15) :970-974